Scholarlink

<p>Gastric cancer (GC) exhibits aggressive behavior and high mortality rates globally. In this respect, the effectiveness of chemotherapy and immunotherapy is hindered by various factors including tumor heterogeneity, immune phenotypes, chronic&#xa0;<i>H</i>. <i>pylori</i> infection, and an immunosuppressive tumor microenvironment (TME). The immunosuppressive TME is fostered by multiple immune cell subpopulations as tumor-associated neutrophils, tumor-associated macrophages, tumor-associated dendritic cells, regulatory T cells, and myeloid-derived suppressor cells (MDSCs). The MDSC abundantly infiltrates gastric TME, which interacts with <i>H. pylori</i> infection and is influenced by reactive oxygen species (ROS), chronic inflammation, and hypoxia. Understanding its cellular and molecular biology of GC is crucial for developing novel therapeutic options. Current preclinical evidence is emerging to support translational oncology on MDSC immunotherapy. This article review suggests MDSC modulation may be a promising avenue for enhancing chemotherapy and immunotherapy responses against GC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Myeloid-derived suppressor cells modulation in the context of tumor microenvironment for gastric cancer

  • 期刊论文

  • 发表日期：

    2025年6月24日

查看全文
  • José Dario Portillo-Miño,
  • Jhon Jairo Calderón,
  • Erika Ruiz-García,
  • Cecilia Monge

摘要

Gastric cancer (GC) exhibits aggressive behavior and high mortality rates globally. In this respect, the effectiveness of chemotherapy and immunotherapy is hindered by various factors including tumor heterogeneity, immune phenotypes, chronic H. pylori infection, and an immunosuppressive tumor microenvironment (TME). The immunosuppressive TME is fostered by multiple immune cell subpopulations as tumor-associated neutrophils, tumor-associated macrophages, tumor-associated dendritic cells, regulatory T cells, and myeloid-derived suppressor cells (MDSCs). The MDSC abundantly infiltrates gastric TME, which interacts with H. pylori infection and is influenced by reactive oxygen species (ROS), chronic inflammation, and hypoxia. Understanding its cellular and molecular biology of GC is crucial for developing novel therapeutic options. Current preclinical evidence is emerging to support translational oncology on MDSC immunotherapy. This article review suggests MDSC modulation may be a promising avenue for enhancing chemotherapy and immunotherapy responses against GC.